Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS1-144 DDI Study with Smoking in Healthy Postmenopausal Females
NCT07534176Phase 1Completed
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- May 2026
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GS1-144, sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. Primary endpoints: Maximum Observed Plasma Concentration up to 72 hours, Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration up to 72 hours and 1 more. Started May 2026; status: completed.
02
Drugs
GS1-144
Beyond the preview
Go deeper on NCT07534176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07534176.